While research has uncovered ever more information about the safety and efficacy of various therapies targeting SARS-CoV-2, the virus behind COVID-19, little is known about how treatments perform in real-world settings. Consequently, a group of researchers known as the National COVID Cohort Collaborative (N3C) sought to study use patterns of potential pharmacologic treatments of COVID-19 in the United States. The team designed a retrospective cohort study of three (3) COVID-19 therapies to better understand the real-world evidence for hydroxychloroquine, remdesivir, and dexamethasone. The results were published recently in the Annals of Internal Medicine.
The National COVID Cohort Collaborative (N3C)
The study team leveraged data from the National COVID Cohort Collaborative (N3C), a large multicenter longitudinal study sponsored by a partnership involving the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), and National Center for Data to Health (CD2H), and NIGMS supported by the Institutional Development Award Networks for Clinical and Translational Research (IDeA-CTR). NCA...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).